PharmaCyte Biotech (PMCB) Files Request for Pre-IND of Pancreatic Cancer Clinical Trial; Shares Climb
PharmaCyte Biotech (OTCQB: PMCB) is trading higher after the clinical-stage biotech announced its first steps toward regulatory approval in the U.S. of the company’s therapy for inoperable pancreatic cancer (LAPC). The company has filed a request for a pre-IND meeting with the U. S. Food and Drug Administration (FDA) for its planned clinical trial designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane® plus gemcitabine. The trial will be open-label and multi-site in nature, with sites in the U.S. and Europe. To view the…







